Menu
PacPremier
Magic Hour
Montecito
SoCal Gas
Loading...
You are here:  Home  >  Central Coast Health Watch  >  Current Article

Amgen sues competitor to block generic version of Sensipar

By   /   Thursday, July 5th, 2018  /   Comments Off on Amgen sues competitor to block generic version of Sensipar

    Print       Email
Thousand Oaks biotech powerhouse Amgen filed a complaint in North Carolina District Court against a competitor seeking to make a generic of its drug Sensipar, used by patients with chronic kidney disease. Accord Healthcare, a Durham, N.C.-based subsidiary of Indian company Intas Pharmaceuticals, allegedly alerted Amgen that it had filed an Abbreviated New Drug Application…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.
    Print       Email

You might also like...

People’s Self-Help Housing secures $50K Bank of America grant

Read More →